Table 2. Outcomes for Patients Treated in Västerbotten and Stockholm Counties.
| Results | Region | |
|---|---|---|
| Västerbotten (n = 52) |
Stockholm (n = 442) |
|
| Drug discontinuation | ||
| Patients who discontinued therapy, No. (%) | 10 (19.2) | 236 (53.4) |
| Person-years | 115.0 | 636.2 |
| Annual drug discontinuation rate | 0.087 | 0.37 |
| HR, crude (95% CI) | NA | 4.6 (2.4-8.7) |
| HR, adjusted (95% CI) | NA | 5.3 (2.6-10.9) |
| Clinical relapse | ||
| Patients with clinical relapse, No. (%) | 3 (5.8) | 84 (19.0) |
| Person-years | 103.2 | 534.7 |
| Annual rate of clinical relapses | 0.03 | 0.16 |
| HR, crude (95% CI) | NA | 5.5 (1.7-17.4) |
| HR, adjusted (95% CI) | NA | 16.9 (2.3-123.1) |
| Gd+ lesions | ||
| Patients with positive scan, No. (%) | 3 (5.8) | 44 (10.0) |
| Patients with valid scan, No. (%)a | 50 (96.2) | 350 (79.2) |
| Patients with positive scan/patients with valid scan | 0.06 | 0.13 |
| OR, crude (95% CI) | NA | 2.2 (0.8-9.5) |
| OR, adjusted (95% CI) | NA | 2.4 (0.8-10.5) |
| AE | ||
| Patients with AE, No. (%) | 2 (3.8) | 188 (42.5) |
| Person-years | 111.2 | 420.7 |
| Incidence of AE per year | 0.02 | 0.45 |
| First-dosing AEs | ||
| Patients with first-dosing AE | 6 | 169 |
| First-dosing AEs/patient | 0.12 | 0.39 |
Abbreviations: AE, adverse event; Gd+, gadolinium enhancing magnetic resonance imaging scan; NA, not applicable; HR, hazard ratio; NA, not applicable; OR, odds ratio.
a
A magnetic resonance imaging scan done at least 3 months after treatment start and before treatment ended.